CA2531056A1 - Therapeutic combination of carnitine and antioxidant polyphenols - Google Patents

Therapeutic combination of carnitine and antioxidant polyphenols Download PDF

Info

Publication number
CA2531056A1
CA2531056A1 CA002531056A CA2531056A CA2531056A1 CA 2531056 A1 CA2531056 A1 CA 2531056A1 CA 002531056 A CA002531056 A CA 002531056A CA 2531056 A CA2531056 A CA 2531056A CA 2531056 A1 CA2531056 A1 CA 2531056A1
Authority
CA
Canada
Prior art keywords
carnitine
acid
composition
hydroxytyrosol
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002531056A
Other languages
English (en)
French (fr)
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creagri Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2531056A1 publication Critical patent/CA2531056A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
CA002531056A 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols Abandoned CA2531056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41783802P 2002-10-11 2002-10-11
US60/417,838 2002-10-11
PCT/US2003/032149 WO2004032873A2 (en) 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols

Publications (1)

Publication Number Publication Date
CA2531056A1 true CA2531056A1 (en) 2004-04-22

Family

ID=32094102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002531056A Abandoned CA2531056A1 (en) 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols

Country Status (6)

Country Link
US (1) US20040132821A1 (enExample)
EP (1) EP1558199A4 (enExample)
JP (1) JP2006506361A (enExample)
AU (1) AU2003279924A1 (enExample)
CA (1) CA2531056A1 (enExample)
WO (1) WO2004032873A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2304964C2 (ru) * 2005-09-26 2007-08-27 Общество с ограниченной ответственностью "Экофарминвест" Способ лечения хронической сердечной недостаточности

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
EA011957B1 (ru) * 2004-11-16 2009-06-30 ДСМ АйПи АССЕТС Б.В. Применение гидрокситирозола для восстановления мышц
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
ES2261088B1 (es) * 2005-04-27 2007-12-01 Laboratorios Alcala Farma, S.L. Uso de hidroxitirosol en la prevencion y tratamiento del ictus cerebral isquemico.
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
WO2007088046A2 (en) 2006-02-01 2007-08-09 Nestec S.A. Nutritional system and methods for increasing longevity
JP2007330191A (ja) * 2006-06-16 2007-12-27 Nihon Yobo Igaku Kenkyusho:Kk メイラード反応を抑制する食品
IT1391928B1 (it) * 2008-08-29 2012-02-02 Giellepi Chemicals S P A Integratore alimentare per il trattamento di neuropatie
WO2010118789A1 (en) 2009-04-17 2010-10-21 Dsm Ip Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
US8796315B2 (en) 2009-06-25 2014-08-05 Darlene E. McCord Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
WO2010151778A2 (en) 2009-06-25 2010-12-29 Darlene Mccord Topical compositions and methods for wound care
WO2011019735A2 (en) 2009-08-10 2011-02-17 Darlene Mccord Nutritional supplements
WO2011109525A1 (en) * 2010-03-02 2011-09-09 Nox Technologies, Inc. Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof
US9144555B2 (en) 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
CN111343993B (zh) * 2017-11-08 2024-03-29 雀巢产品有限公司 高香草醇(hva)、hva异构体、制备包含此类化合物的组合物的方法、以及使用此类化合物的方法
CN113615833A (zh) * 2021-07-01 2021-11-09 泓博元生命科技（深圳）有限公司 一种用于改善心血管的线粒体营养素组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US6337320B1 (en) * 1996-10-11 2002-01-08 Thione International, Inc. Reparatives for ultraviolet radiation skin damage
DE19824346A1 (de) * 1998-06-02 1999-12-09 Peter Schleicher Nahrungsergänzungsmittel
IT1299197B1 (it) * 1998-06-30 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante, antiproliferativa, energetica e atta a migliorare l'utilizzazione metabolica del glucosio.
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6746706B1 (en) * 1998-12-22 2004-06-08 Lipton, Division Of Conopco, Inc. Food compositions fortified with anti-oxidants
US6437004B1 (en) * 2000-04-06 2002-08-20 Nicholas V. Perricone Treatment of skin damage using olive oil polyphenols
IT1317036B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti da piante
JP3820218B2 (ja) * 2000-09-01 2006-09-13 クレアグリ， インコーポレイテッド 植物水からヒドロキシチロソール富化組成物を得る方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2304964C2 (ru) * 2005-09-26 2007-08-27 Общество с ограниченной ответственностью "Экофарминвест" Способ лечения хронической сердечной недостаточности

Also Published As

Publication number Publication date
US20040132821A1 (en) 2004-07-08
EP1558199A2 (en) 2005-08-03
EP1558199A4 (en) 2006-06-28
WO2004032873A2 (en) 2004-04-22
JP2006506361A (ja) 2006-02-23
AU2003279924A1 (en) 2004-05-04
WO2004032873A3 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
CA2341973C (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
US20040132821A1 (en) Therapeutic combination of carnitine and antioxidant polyphenols
Hayashi et al. Effect of astaxanthin-rich extract derived from Paracoccus carotinifaciens on cognitive function in middle-aged and older individuals
CA2344893C (en) Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
JP2013503853A (ja) 神経変性または神経・筋変性疾患の治療方法およびその治療薬
US8318954B2 (en) Cleavable carnitine compound
ITRM980433A1 (it) Composizione ad attivita' antiossidante antiproliferativa energetica e atta a migliorare l'utilizzazione metabolica del glucosio
KR100304312B1 (ko) 아연이보충된전립선추출물
WO2006015774A1 (de) Physiologisch verträgliche zusammensetzung enthaltend alphaliponsaüre, kreatin und ein phospholipid
EP0428608A1 (fr) Compositions pharmaceutiques et/ou dietetiques contenant de la l-carnitine et de la l-lysine
MXPA01002045A (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND&agr;-LIPOIC ACID
EP1897549B1 (en) Radical scavenger and active oxygen eliminating agent
JPH11343234A (ja) テトラヒドロクルクミン誘導体を含有する組成物
WO2006042666A1 (de) R-(+)-α-LIPONSÄURE ZUR PRÄVENTION VON DIABETES
EP1661562A1 (en) Sphingolipids in treatment and prevention of steatosis
JP2862676B2 (ja) 亜鉛を補充された前立腺抽出物
WO2008037047A1 (en) Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued